Edgewise Therapeutics, Inc. (EWTX): Price and Financial Metrics


Edgewise Therapeutics, Inc. (EWTX): $10.23

-0.54 (-5.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EWTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EWTX Stock Price Chart Interactive Chart >

Price chart for EWTX

EWTX Price/Volume Stats

Current price $10.23 52-week high $14.52
Prev. close $10.77 52-week low $5.41
Day low $9.89 Volume 183,071
Day high $11.08 Avg. volume 152,709
50-day MA $9.32 Dividend yield N/A
200-day MA $9.14 Market Cap 646.68M

Edgewise Therapeutics, Inc. (EWTX) Company Bio


Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.


EWTX Latest News Stream


Event/Time News Detail
Loading, please wait...

EWTX Latest Social Stream


Loading social stream, please wait...

View Full EWTX Social Stream

Latest EWTX News From Around the Web

Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PT (12:45 pm ET). The presentation will be webcast live; a link for the webcast can be found on the Edgewise e

Business Wire | January 4, 2023

Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

BOULDER, Colo., December 21, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today plans to host a virtual investor call on Tuesday, January 3, 2023, at 8:30 am ET. The webcast event will feature a presentation of preclinical results for its lead cardiac program candidate, EDG-7500, initially targeting patients wi

Yahoo | December 21, 2022

Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

BOULDER, Colo., December 20, 2022--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO)

Yahoo | December 20, 2022

Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 14, 2022

Edgewise Therapeutics to Present at Upcoming Investor Conferences

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following upcoming investor conferences: Stifel 2022 Healthcare Conference Presentation: Wednesday, November 16, 2022, at 3:00 pm ET Piper Sandler 34th Annual Healthcare Conference Pr

Business Wire | November 9, 2022

Read More 'EWTX' Stories Here

EWTX Price Returns

1-mo 14.43%
3-mo 8.83%
6-mo 0.79%
1-year -24.78%
3-year N/A
5-year N/A
YTD 14.43%
2022 -41.49%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6256 seconds.